✦ LIBER ✦

Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: A strategy to improve the quality of gynecologic cancer clinical research

✍ Scribed by Maurie Markman

Book ID: 113961638
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 105 KB
Volume: 110
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2008.05.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of a European Organization f

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report

✍ A Cull; S Howat; E Greimel; A.-C Waldenstrom; J Arraras; A Kudelka; L Chauvenet; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Addition of bevacizumab to chemotherapy

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

✍ Ossenkoppele, G. J.; Stussi, G.; Maertens, J.; van Montfort, K.; Biemond, B. J.; 📂 Article 📅 2012 🏛 American Society of Hematology 🌐 English ⚖ 273 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB